Focus Partners Wealth Purchases Shares of 4,469 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Focus Partners Wealth bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,469 shares of the specialty pharmaceutical company's stock, valued at approximately $551,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Barclays PLC raised its holdings in shares of Jazz Pharmaceuticals by 19.1% in the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock valued at $4,369,000 after acquiring an additional 6,289 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Park Avenue Securities LLC now owns 2,521 shares of the specialty pharmaceutical company's stock valued at $310,000 after acquiring an additional 412 shares in the last quarter. Arkadios Wealth Advisors bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $716,000. Aaron Wealth Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $301,000. Finally, Ellsworth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after acquiring an additional 149 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Up 0.2%

Shares of JAZZ stock traded up $0.25 during trading hours on Friday, reaching $108.07. 958,795 shares of the company's stock were exchanged, compared to its average volume of 851,979. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market cap of $6.66 billion, a PE ratio of 15.22, a PEG ratio of 1.04 and a beta of 0.38. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock's fifty day moving average price is $112.87 and its two-hundred day moving average price is $121.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same quarter in the previous year, the firm posted $2.68 EPS. Jazz Pharmaceuticals's revenue was down .5% on a year-over-year basis. Research analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan purchased 100,000 shares of the company's stock in a transaction dated Friday, May 9th. The shares were acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the purchase, the director now owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at $66,940,366.50. This trade represents a 1.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,236 shares of company stock worth $3,956,190. Insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.